Upcoming Financial Results Announcement for Iterum Therapeutics
Iterum Therapeutics to Announce Key Financial Results
Iterum Therapeutics plc (NASDAQ: ITRM), a pioneer in developing innovative oral and IV antibiotics, will unveil its fourth quarter and full year financial results for 2024 on February 7, 2025. This major announcement is crucial not only for the company but also for its stakeholders who are invested in the fight against multi-drug resistant pathogens.
Details of the Financial Results Release
The company plans to disclose its financial performance before U.S. markets open. Following the release, Iterum’s management will host a conference call at 8:30 a.m. ET. This call will offer a platform for discussing the financial results extensively and will provide insights into the strategic directions of the business.
Accessing the Conference Call
Investors and interested parties can participate in the call by dialing 833-470-1428 for domestic calls or 404-975-4839 for international access. It's crucial that participants refer to Access Code 719739 when joining. Moreover, those who prefer to pre-register can do so through the designated conference call link.
About Iterum Therapeutics
Iterum Therapeutics is committed to developing novel anti-infective medications aimed at addressing the growing challenge of multi-drug resistant bacteria. The company's leading candidate, sulopenem, represents a significant advancement in the treatment options available today. With both oral and IV formulations, sulopenem is positioned to combat various gram-negative, gram-positive, and anaerobic bacteria resistant to existing antibiotics.
Regulatory Approvals and Designations
Notably, Iterum has received FDA approval for its oral formulation, ORLYNVAH™. This drug has been sanctioned for the treatment of uncomplicated urinary tract infections caused by specific pathogens in adult women who have limited or no alternative treatment options. Furthermore, Iterum has secured the Qualified Infectious Disease Product (QIDP) and Fast Track designations, reinforcing the urgency and significance of its antibiotic development efforts.
The Mission and Future Vision
As the world grapples with the increasing threat of antibiotic resistance, Iterum’s mission has never been more vital. The company aims to improve patient outcomes by introducing effective anti-infectives that tackle the root cause of treatment failures in serious and life-threatening conditions.
Investor Relations
For more updates or inquiries about Iterum Therapeutics’ financial outlook or product pipeline, interested parties can reach out directly to the Chief Financial Officer, Judy Matthews, at 312-778-6073 or via email.
Frequently Asked Questions
What financial results will Iterum Therapeutics announce?
Iterum Therapeutics will report its fourth quarter and full year financial results for 2024, providing insights into its performance and future strategies.
When will the conference call take place?
The conference call will be held on February 7, 2025, at 8:30 a.m. ET following the financial results release.
How can one participate in the conference call?
To participate, dial 833-470-1428 for domestic calls or 404-975-4839 for international access, using Access Code 719739.
What is sulopenem?
Sulopenem is Iterum Therapeutics' leading anti-infective compound developed to treat infections caused by multi-drug resistant bacteria.
Who should investors contact for more information?
Investors are encouraged to contact Judy Matthews, the Chief Financial Officer of Iterum Therapeutics, for inquiries and additional details.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.